Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples